Table of Contents
UprimaŽ (apomorphine HCl tablets) sublingual Presentation to the Urology Subcommittee of the Advisory Committee for Reproductive Health Drugs April 10, 2000 TAP HOLDINGS INC.
Speakers
TAP Participants
TAP Participants (cont.)
TAP Consultants
TAP Consultants
TAP Presentations
Topics Identified in FDA Briefing Document
Erectile Dysfunction (ED)
Erectile Dysfunction
Erectile Dysfunction
Age Related Changes in Erectile Status
Massachusetts Male Aging Study
ED Population
Introduction to Apomorphine
Introduction to UprimaŽ
Introduction to UprimaŽ
Proposed Indication
Doses
Rationale for UprimaŽ Treatment of ED
Rationale for UprimaŽ Treatment of ED
UprimaŽ Clinical Trials
|
Author: Andrea_Poffenberger
|